Satavaptan for the management of ascites in cirrhosis: Efficacy and safety across the spectrum of ascites severity

Florence Wong, Hugh Watson, Alexander Gerbes, Hendrik Vilstrup, Salvatore Badalamenti, Mauro Bernardi, Pere Ginès

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Objective: Satavaptan, a vasopressin V2 receptor antagonist, has been shown to improve the control of ascites in cirrhosis in short-term phase II studies. The aim of this study was to evaluate the efficacy and safety of satavaptan in three different populations of patients with cirrhosis and ascites. Methods: 1200 patients were included in three randomised double-blind studies comparing satavaptan with placebo in uncomplicated ascites (study 1: n=463 patients) and difficult-to-treat ascites, with and without concomitant diuretic treatment (studies 2 and 3: n=497 and n=240 patients, respectively). Results: Satavaptan was not more effective than placebo in the control of ascites in any of the populations studied as estimated by the primary efficacy endpoints: worsening of ascites (study 1) and the cumulative number of large-volume paracenteses during 12 weeks (studies 2 and 3). Nevertheless, some of the secondary efficacy endpoints related to the treatment of ascites were met in the three studies, suggesting a slight advantage of satavaptan over placebo in delaying ascites formation. Moreover, satavaptan was more effective than placebo in improving the serum sodium concentration in patients with hyponatraemia. The incidence of major complications of cirrhosis during follow-up did not differ significantly between the satavaptan and placebo groups in the three studies. Overall, the rate of any treatment-related adverse events, serious treatment-related events and treatment-related events leading to permanent discontinuation of treatment did not differ significantly between the treatment groups. However, in study 2 mortality was higher in patients treated with satavaptan compared with placebo (HR 1.47; 95% CI 1.01 to 2.15); no significant differences in mortality between the two groups were observed in the other two studies. No specific cause for the increased mortality was identified. Most deaths were associated with known complications of liver cirrhosis. Conclusion: Satavaptan, alone or in combination with diuretics, is not clinically beneficial in the long-term management of ascites in cirrhosis.

Original languageEnglish
Pages (from-to)108-116
Number of pages9
JournalGut
Volume61
Issue number1
DOIs
Publication statusPublished - Jan 2012

Fingerprint

Ascites
Fibrosis
Safety
Placebos
Diuretics
Therapeutics
Mortality
Paracentesis
satavaptan
Vasopressin Receptors
Hyponatremia
Double-Blind Method
Liver Cirrhosis
Population
Sodium
Incidence
Serum

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Satavaptan for the management of ascites in cirrhosis : Efficacy and safety across the spectrum of ascites severity. / Wong, Florence; Watson, Hugh; Gerbes, Alexander; Vilstrup, Hendrik; Badalamenti, Salvatore; Bernardi, Mauro; Ginès, Pere.

In: Gut, Vol. 61, No. 1, 01.2012, p. 108-116.

Research output: Contribution to journalArticle

Wong, Florence ; Watson, Hugh ; Gerbes, Alexander ; Vilstrup, Hendrik ; Badalamenti, Salvatore ; Bernardi, Mauro ; Ginès, Pere. / Satavaptan for the management of ascites in cirrhosis : Efficacy and safety across the spectrum of ascites severity. In: Gut. 2012 ; Vol. 61, No. 1. pp. 108-116.
@article{9a751e994b4b4c27a69a1f490839801c,
title = "Satavaptan for the management of ascites in cirrhosis: Efficacy and safety across the spectrum of ascites severity",
abstract = "Objective: Satavaptan, a vasopressin V2 receptor antagonist, has been shown to improve the control of ascites in cirrhosis in short-term phase II studies. The aim of this study was to evaluate the efficacy and safety of satavaptan in three different populations of patients with cirrhosis and ascites. Methods: 1200 patients were included in three randomised double-blind studies comparing satavaptan with placebo in uncomplicated ascites (study 1: n=463 patients) and difficult-to-treat ascites, with and without concomitant diuretic treatment (studies 2 and 3: n=497 and n=240 patients, respectively). Results: Satavaptan was not more effective than placebo in the control of ascites in any of the populations studied as estimated by the primary efficacy endpoints: worsening of ascites (study 1) and the cumulative number of large-volume paracenteses during 12 weeks (studies 2 and 3). Nevertheless, some of the secondary efficacy endpoints related to the treatment of ascites were met in the three studies, suggesting a slight advantage of satavaptan over placebo in delaying ascites formation. Moreover, satavaptan was more effective than placebo in improving the serum sodium concentration in patients with hyponatraemia. The incidence of major complications of cirrhosis during follow-up did not differ significantly between the satavaptan and placebo groups in the three studies. Overall, the rate of any treatment-related adverse events, serious treatment-related events and treatment-related events leading to permanent discontinuation of treatment did not differ significantly between the treatment groups. However, in study 2 mortality was higher in patients treated with satavaptan compared with placebo (HR 1.47; 95{\%} CI 1.01 to 2.15); no significant differences in mortality between the two groups were observed in the other two studies. No specific cause for the increased mortality was identified. Most deaths were associated with known complications of liver cirrhosis. Conclusion: Satavaptan, alone or in combination with diuretics, is not clinically beneficial in the long-term management of ascites in cirrhosis.",
author = "Florence Wong and Hugh Watson and Alexander Gerbes and Hendrik Vilstrup and Salvatore Badalamenti and Mauro Bernardi and Pere Gin{\`e}s",
year = "2012",
month = "1",
doi = "10.1136/gutjnl-2011-300157",
language = "English",
volume = "61",
pages = "108--116",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Satavaptan for the management of ascites in cirrhosis

T2 - Efficacy and safety across the spectrum of ascites severity

AU - Wong, Florence

AU - Watson, Hugh

AU - Gerbes, Alexander

AU - Vilstrup, Hendrik

AU - Badalamenti, Salvatore

AU - Bernardi, Mauro

AU - Ginès, Pere

PY - 2012/1

Y1 - 2012/1

N2 - Objective: Satavaptan, a vasopressin V2 receptor antagonist, has been shown to improve the control of ascites in cirrhosis in short-term phase II studies. The aim of this study was to evaluate the efficacy and safety of satavaptan in three different populations of patients with cirrhosis and ascites. Methods: 1200 patients were included in three randomised double-blind studies comparing satavaptan with placebo in uncomplicated ascites (study 1: n=463 patients) and difficult-to-treat ascites, with and without concomitant diuretic treatment (studies 2 and 3: n=497 and n=240 patients, respectively). Results: Satavaptan was not more effective than placebo in the control of ascites in any of the populations studied as estimated by the primary efficacy endpoints: worsening of ascites (study 1) and the cumulative number of large-volume paracenteses during 12 weeks (studies 2 and 3). Nevertheless, some of the secondary efficacy endpoints related to the treatment of ascites were met in the three studies, suggesting a slight advantage of satavaptan over placebo in delaying ascites formation. Moreover, satavaptan was more effective than placebo in improving the serum sodium concentration in patients with hyponatraemia. The incidence of major complications of cirrhosis during follow-up did not differ significantly between the satavaptan and placebo groups in the three studies. Overall, the rate of any treatment-related adverse events, serious treatment-related events and treatment-related events leading to permanent discontinuation of treatment did not differ significantly between the treatment groups. However, in study 2 mortality was higher in patients treated with satavaptan compared with placebo (HR 1.47; 95% CI 1.01 to 2.15); no significant differences in mortality between the two groups were observed in the other two studies. No specific cause for the increased mortality was identified. Most deaths were associated with known complications of liver cirrhosis. Conclusion: Satavaptan, alone or in combination with diuretics, is not clinically beneficial in the long-term management of ascites in cirrhosis.

AB - Objective: Satavaptan, a vasopressin V2 receptor antagonist, has been shown to improve the control of ascites in cirrhosis in short-term phase II studies. The aim of this study was to evaluate the efficacy and safety of satavaptan in three different populations of patients with cirrhosis and ascites. Methods: 1200 patients were included in three randomised double-blind studies comparing satavaptan with placebo in uncomplicated ascites (study 1: n=463 patients) and difficult-to-treat ascites, with and without concomitant diuretic treatment (studies 2 and 3: n=497 and n=240 patients, respectively). Results: Satavaptan was not more effective than placebo in the control of ascites in any of the populations studied as estimated by the primary efficacy endpoints: worsening of ascites (study 1) and the cumulative number of large-volume paracenteses during 12 weeks (studies 2 and 3). Nevertheless, some of the secondary efficacy endpoints related to the treatment of ascites were met in the three studies, suggesting a slight advantage of satavaptan over placebo in delaying ascites formation. Moreover, satavaptan was more effective than placebo in improving the serum sodium concentration in patients with hyponatraemia. The incidence of major complications of cirrhosis during follow-up did not differ significantly between the satavaptan and placebo groups in the three studies. Overall, the rate of any treatment-related adverse events, serious treatment-related events and treatment-related events leading to permanent discontinuation of treatment did not differ significantly between the treatment groups. However, in study 2 mortality was higher in patients treated with satavaptan compared with placebo (HR 1.47; 95% CI 1.01 to 2.15); no significant differences in mortality between the two groups were observed in the other two studies. No specific cause for the increased mortality was identified. Most deaths were associated with known complications of liver cirrhosis. Conclusion: Satavaptan, alone or in combination with diuretics, is not clinically beneficial in the long-term management of ascites in cirrhosis.

UR - http://www.scopus.com/inward/record.url?scp=83555178537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83555178537&partnerID=8YFLogxK

U2 - 10.1136/gutjnl-2011-300157

DO - 10.1136/gutjnl-2011-300157

M3 - Article

C2 - 21836029

AN - SCOPUS:83555178537

VL - 61

SP - 108

EP - 116

JO - Gut

JF - Gut

SN - 0017-5749

IS - 1

ER -